Well it looks like Bota doesn't want to diversify out of self...

Well it looks like Bota doesn't want to diversify out of self limiting respiratory diseases. Which means there will always be debate about the cost benefit of shaving 1 day off symptoms of influenza or rhinovirus or RSV.

There's still debate whether Medimmune's RSV drug is cost effective & efficacious but it didn't stop it earning $1 billion per annum in a small cohort of the population not long ago.

My 2c.